Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28769254 | 0.85 | CTSK (0.35) | BLMPMP22HSD17B10CTSKCHRM2 | |
| SCHEMBL17801996 | 0.84 | MEN1 (0.41) | BLMPMP22HSD17B10CTSKCHRM2 | |
| SCHEMBL29749278 | 0.83 | CTSK (0.36) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL19169986 | 0.80 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21224845 | 0.79 | CHRNB2 (0.38) | BLMPMP22HSD17B10CTSKCHRM2 | |
| SCHEMBL28497762 | 0.79 | CHRNB2 (0.38) | BLMPMP22HSD17B10CTSKCHRM2 | |
| SCHEMBL3827409 | 0.76 | CTSK (0.36) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL31524126 | 0.76 | BLM (0.48) | BLMPMP22HSD17B10CHRM2CHRM4 | |
| SCHEMBL30622147 | 0.76 | BLM (0.48) | BLMPMP22HSD17B10CHRM2CHRM4 | |
| SCHEMBL25969214 | 0.76 | BLM (0.48) | BLMPMP22HSD17B10CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3903826-B1 | BIOMOLECULE CONJUGATES | CELGENE CORP (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4289483-A2 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-114656483-A | Biomolecular conjugates | 细胞基因公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3903826-A1 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10335495-B2 | Biomolecule conjugates | CELGENE CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | CELGENE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| EP-3226910-A1 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016090157-A1 | BIOMOLECULE CONJUGATES | CELGENE CORPORATION (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335495-B2 | Biomolecule conjugates | DNPEP, NAPA, NCL | BLM 2479/4885PMP22 3680/4885HSD17B10 2325/4885 |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | DNPEP, NAPA, NCL | BLM 2479/4885PMP22 3680/4885HSD17B10 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.